This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-19. Anything still debated is marked as such rather than presented as settled.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
=== Operation Enduring Freedom VI, 2005–2008 === The 1st Brigade of the 82nd deployed in April 2005 in support of OEF 6, and returned in April 2006. 1st Battalion, 325th Infantry Regiment deployed in support of OEF 6 from July through November 2005. In March 2006, 3rd Battalion (General Support), 82nd Aviation was selected to augment a special operations task force using CH-47 Chinooks and UH-60 Black Hawks. The task force consisted of 75th Ranger Regiment, Special Forces, and 160th Special Operations Aviation Regiment (Airborne). 2007 February 18, seven soldiers from the task force died in a helicopter crash. The deployment would end a month later (March 2007). In January 2007, then Maj. Gen. David M. Rodriguez deployed the division headquarters to Bagram Air Base, Afghanistan, accompanied by 4th BCT and the Aviation Brigade, as Commander, Combined Joint Task Force-82 (CJTF-82) and Regional Command – East for Operation Enduring Freedom VIII. The 3d BCT, 10th Mountain Division (Light Infantry) was extended for 120 days to increase the troop strength against the Taliban spring offensive. Extended to 15-month deployment, 4th BCT, which included 1–508th Infantry Regiment, 2–508th Infantry Regiment, and 4–73rd Cavalry Regiment, 2–321st Field Artillery, and 782nd Brigade Support Battalion, was commanded by then Col. Martin P. Schweitzer and remained in Khowst Province from January 2007 until April 2008. The 2–508th IR worked to establish and maintain firebases in and around the Ghazni province while actively patrolling their operational area.
=== Patterns === In TCM, "pattern" (证; zhèng) refers to a "pattern of disharmony" or "functional disturbance" within the functional entities of which the TCM model of the body is composed. There are disharmony patterns of qi, xuě, the body fluids, the zàng-fǔ, and the meridians. They are ultimately defined by their symptoms and signs (i.e., for example, pulse and tongue findings). In clinical practice, the identified pattern usually involves a combination of affected entities (compare with typical examples of patterns). The concrete pattern identified should account for all the symptoms a person has.
Under Khosrow II, the Sassanids occupied the Levant and Egypt and advanced into Asia Minor, and the Avars and Slavs raided in the Balkans. The Empire's control of Italy also weakened. After successfully repelling a siege of Constantinople in 626, Heraclius won a decisive victory at the Battle of Nineveh, eventually defeating the Sassanids later that year. The triumph would prove short-lived. The Arab conquests soon saw the conquest of the Levant, Egypt, and the Sassanid Empire by the newly formed Arab Rashidun Caliphate. By Heraclius' death in 641, the empire had been severely reduced economically and territorially—the loss of the wealthy eastern provinces had deprived the empire of as much as three-quarters of its revenue. The next century is poorly documented. Arab raids into Asia Minor started quickly, and the Empire responded by holding fortified centres and avoiding battle wherever possible. Although Anatolia was invaded annually, it avoided permanent Arab occupation. The outbreak of the First Fitna in 656 gave the Empire breathing space, which it used sensibly: some order was restored in the Balkans by Constans II (r. 641–668) following his administrative reorganisation which over time evolved into the "theme system", a structure that allocated troops to defend specific provinces. Constantine IV (r. 668–685) repelled the Arab efforts to capture Constantinople in the 670s using Greek fire, but suffered a reversal against the Bulgars, who soon established an empire in the northern Balkans.
Sources: en.wikipedia.org
== History == Molecular engineering was first mentioned in the research literature in 1956 by Arthur R. von Hippel, who defined it as "… a new mode of thinking about engineering problems. Instead of taking prefabricated materials and trying to devise engineering applications consistent with their macroscopic properties, one builds materials from their atoms and molecules for the purpose at hand." This concept was echoed in Richard Feynman's seminal 1959 lecture There's Plenty of Room at the Bottom, which is widely regarded as giving birth to some of the fundamental ideas of the field of nanotechnology. In spite of the early introduction of these concepts, it was not until the mid-1980s with the publication of Engines of Creation: The Coming Era of Nanotechnology by Drexler that the modern concepts of nano and molecular-scale science began to grow in the public consciousness. The discovery of electrically conductive properties in polyacetylene by Alan J. Heeger in 1977 effectively opened the field of organic electronics, which has proved foundational for many molecular engineering efforts. Design and optimization of these materials has led to a number of innovations including organic light-emitting diodes and flexible solar cells.
==== Coloration ==== Mammalian coats are colored for a variety of reasons, the major selective pressures including camouflage, sexual selection, communication, and thermoregulation. Coloration in both the hair and skin of mammals is mainly determined by the type and amount of melanin; eumelanins for brown and black colors and pheomelanin for a range of yellowish to reddish colors, giving mammals an earth tone. Some mammals have more vibrant colors; certain monkeys such mandrills and vervet monkeys, and opossums such as the Mexican mouse opossums and Derby's woolly opossums, have blue skin due to light diffraction in collagen fibers. Many sloths appear green because their fur hosts green algae; this may be a symbiotic relation that affords camouflage to the sloths. Camouflage is a powerful influence in a large number of mammals, as it helps to conceal individuals from predators or prey. In arctic and subarctic mammals such as the arctic fox (Alopex lagopus), collared lemming (Dicrostonyx groenlandicus), stoat (Mustela erminea), and snowshoe hare (Lepus americanus), seasonal color change between brown in summer and white in winter is driven largely by camouflage. Some arboreal mammals, notably primates and marsupials, have shades of violet, green, or blue skin on parts of their bodies, indicating some distinct advantage in their largely arboreal habitat due to convergent evolution.
Barker often appeared in fiction as himself, usually in a cameo appearance, in shows including The Nanny, The Bold and the Beautiful Futurama, and How I Met Your Mother.In 1996, Barker played himself in the Adam Sandler comedy Happy Gilmore. In one scene, Barker beats up Gilmore after an altercation arising from their teaming up in a Pro-Am Golf Tournament. According to Sandler, the original choice for that scene was Ed McMahon, but Sandler said that McMahon was not fond of the script and they got Barker because of Chuck Norris training Barker in the martial arts. Barker also played himself in the animated series Family Guy, starting in 2001 with the episode "Screwed the Pooch" with his last appearance being in 2008 in the episode "Tales of a Third Grade Nothing". In 2007, during a CBS prime-time special commemorating Barker's career, the fight scene from Happy Gilmore was shown, after which Sandler made a surprise appearance on stage to read a poem paying tribute to Barker. In 2015, during Comedy Central's "Night of Too Many Stars" benefit show to battle autism, Barker and Sandler reunited for a video featuring the two of them in a follow-up fight at the hospital, which ends with both of them dying and going to heaven. However, Barker did play characters apart from himself in Bonanza, as a character named Mort in the 1960 episode "Denver McKee", and as a small business owner named Bob Barnacle in "Sanctuary!", an episode of the Nickelodeon animated series SpongeBob SquarePants.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.